

## DAFTAR PUSTAKA

1. Keyt H, Faverio P, Restrepo MI. Prevention of ventilator-associated pneumonia in the intensive care unit: a review of the clinically relevant recent advancements. *Indian J Med Res* 2014; 139: 814.
2. Afifi MH, Elhendy AA, Eltaweel MM, et al. Biomarker predictors of survival in patients with ventilator-associated pneumonia. *Menoufia Med J* 2015; 28: 254.
3. Abd El Halim A, Attia A, Zytoun T, et al. The diagnostic and prognostic value of serum procalcitonin among ventilator associated pneumonia patients. *Open J Respir Dis* 2013; 3: 73.
4. Noer SF. Pola bakteri dan resistensinya terhadap antibiotik yang ditemukan pada air dan udara ruang instalasi rawat khusus RSUP Dr. *Maj Farm dan Farmakol* 2012; 16: 73–78.
5. Force ERST. Ventilator-associated pneumonia. *Eur Respir J* 2001; 17: 1034–1045.
6. Elkhashab AEA, Swelem RS, Alaa El Din A, et al. Etiological and prognostic values of procalcitonin in hospital-acquired pneumonia. *Egypt J chest Dis Tuberc* 2014; 63: 201–206.
7. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. *Eur Respir J* 2009; 34: 1364–1375.
8. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. *Am J Respir Crit Care Med* 2002; 165: 867–903.
9. Bonten MJM. Ventilator-associated pneumonia: preventing the inevitable. *Clin Infect Dis* 2011; 52: 115–121.
10. Guggenbichler JP, Assadian O, Boeswald M, et al. Incidence and clinical implication of nosocomial infections associated with implantable biomaterials–catheters, ventilator-associated pneumonia, urinary tract infections. *GMS Krankenhhyg Interdiszip*; 6.
11. Zolfaghari PS, Wyncoll DLA. The tracheal tube: gateway to ventilator-associated pneumonia. *Crit Care* 2011; 15: 1–8.
12. Cardoso TC, Lopes LM, Carneiro AH. A case-control study on risk factors for early-onset respiratory tract infection in patients admitted in ICU. *BMC Pulm Med* 2007; 7: 1–6.
13. Costa PS, Scholte LLS, Reis MP, et al. Bacteria and genes involved in arsenic speciation in sediment impacted by long-term gold mining. *PLoS One* 2014; 9: e95655.
14. Wiryana M. Tinjauan pustaka VENTILATOR ASSOCIATED PNEUMONIA Made Wiryana Bagian/SMF Ilmu Anestesi dan Reanimasi, FK Unud/RSUP Sanglah Denpasar. 2015; 8: 254–268.
15. Vacheron C-H, Lepape A, Savey A, et al. Increased incidence of ventilator-acquired pneumonia in coronavirus disease 2019 patients: a multicentric cohort study. *Crit Care Med* 2022; 50: 449.
16. Safdar N, Dezfulian C, Collard HR, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. *Crit Care Med* 2005; 33: 2184–2193.
17. Charles MVP, Kali A, Easow JM, et al. Ventilator-associated pneumonia. *Australas Med J* 2014; 7: 334.
18. Evans B. Best-practice protocols: VAP prevention. *Nurs Manage* 2005; 36: 10–16.
19. O’Grady NP, Murray PR, Ames N. Preventing ventilator-associated pneumonia: does the evidence support the practice? *Jama* 2012; 307: 2534–2539.

20. Suryo J. *Herbal Penyembuh Gangguan Sistem Pernapasan: Pneumonia–Kanker Paru-Paru-TB-Bronkitis-Pleurisi*. Bentang Pustaka, 2010.
21. Hooven TA, Polin RA. Ventilator-Associated Pneumonia. *Newborn Lung Neonatol Quest Controv Third Ed* 2018; 147–159.
22. Miller PR, Johnson III JC, Karchmer T, et al. National nosocomial infection surveillance system: from benchmark to bedside in trauma patients. *J Trauma Acute Care Surg* 2006; 60: 98–103.
23. Porzecanski I, Bowton DL. Diagnosis and treatment of ventilator-associated pneumonia. *Chest* 2006; 130: 597–604.
24. Focaccia R, Gomes Da Conceicao OJ. Pneumonia hospitalar. *Rev Bras Med* 1994; 51: 95–98.
25. Gorman SK, Stewart L-MM, Slavik RS, et al. Identifying missed opportunities to curtail antimicrobial therapy for presumed ventilator-associated pneumonia using the clinical pulmonary infection score. *Can J Hosp Pharm* 2009; 62: 217.
26. Misnadiarly. *Penyakit Infeksi Saluran Napas Pneumonia pada Anak, Orang dewasa, Usia Lanjut*. 1st ed. Jakarta: Pustaka Obor Populer, 2008.
27. Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human procalcitonin. *FEBS Lett* 1984; 167: 93–97.
28. Vijayan AL, Ravindran S, Saikant R, et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. *J intensive care* 2017; 5: 1–7.
29. O'GRADY NP, PREAS HL, Pugin J, et al. Local inflammatory responses following bronchial endotoxin instillation in humans. *Am J Respir Crit Care Med* 2001; 163: 1591–1598.
30. Meisner M. Update on Procalcitonin Measurements. *Ann Lab Med* 2014; 34: 263–273.
31. Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. *Physiol Res* 2000; 49: S57–S62.
32. Lippi G, Sanchis-Gomar F. Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. *World J Gastroenterol* 2017; 23: 8283.
33. Napolitano LM. Use of severity scoring and stratification factors in clinical trials of Hospital-acquired and ventilator-associated pneumonia. *Clin Infect Dis* 2010; 51: 67–80.
34. Tanriverdi H, Tor MM, Kart L, et al. Prognostic value of serum procalcitonin and C-reactive protein levels in critically ill patients who developed ventilator-associated pneumonia. *Ann Thorac Med* 2015; 10: 137.
35. Müller B. Procalcitonin and Ventilator-associated Pneumonia: Yet Another Breath of Fresh Air. *Am J Respir Crit Care Med* 2005; 171: 1–2.
36. Seligman R, Seligman BGS, Teixeira PJZ. Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia. *J Bras Pneumol* 2011; 37: 495–503.
37. Koncoro H, Suta IB. Peran Prokalsitonin dalam Bidang Pulmonologi.
38. Palazzo SJ, Simpson T, Schnapp L. Biomarkers for ventilator-associated pneumonia: review of the literature. *Hear Lung* 2011; 40: 293–298.
39. El-dib AS, El-Srougy HA. Diagnostic and prognostic role of procalcitonin in CAP. *Egypt J Chest Dis Tuberc* 2015; 64: 871–875.
40. Zulkifli Z, br Haloho A, Theodorus T, et al. Hubungan Nilai Prokalsitonin dengan Angka Mortalitas Pasien Ventilator Associated Pneumonia di Unit Perawatan Intensif RSUP Dr. Moh. Hoesin Palembang. *Maj Anest dan Crit Care* 2017; 35: 165–176.

41. Schuiteman S, Albin O. Association Between End-of-Treatment Procalcitonin Levels with Mortality & Recurrent Ventilator-Associated Pneumonia. *Open Forum Infect Dis* 2022; 9: ofac492.1790.
42. Alessandri F, Pugliese F, Angeletti S, et al. Procalcitonin in the Assessment of Ventilator Associated Pneumonia: A Systematic Review. *Adv Exp Med Biol* 2021; 1323: 103–114.
43. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997; 336: 243–250.
44. Rosón B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. *Clin Infect Dis* 2001; 33: 158–165.
45. Ewig S, De Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. *Thorax* 2004; 59: 421–427.
46. Chen L, Lu XY, Zhu CQ. Prognostic value of albumin-red cell distribution width score in patients with severe community-acquired pneumonia. *Ann Cardiothorac Surg* 2020; 9: 759–765.
47. Viasus D, Garcia-Vidal C, Simonetti A, et al. Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. *J Infect* 2013; 66: 415–423.
48. Lee J, Kim K, Jo YH, et al. Severe thinness is associated with mortality in patients with community-acquired pneumonia: a prospective observational study. *Am J Emerg Med* 2015; 33: 209–213.
49. Ghatas TS, Elfaizy MW. C-Reactive Protein and Procalcitonin in Predicting Treatment Failure in Community Acquired Pneumonia. *Al-Azhar Int Med J*; 4. Epub ahead of print 2023. DOI: 10.58675/2682-339x.1718.
50. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. *Thorax* 2006; 61: 419–424.
51. Shah BA, Ahmed W, Dhobi GN, et al. Validity of pneumonia severity index and CURB-65 severity scoring systems in community acquired pneumonia in an Indian setting. *Indian J Chest Dis Allied Sci* 2010; 52: 9–17.
52. Pawar M, Mehta Y, Khurana P, et al. Ventilator-associated pneumonia: Incidence, risk factors, outcome, and microbiology. *J Cardiothorac Vasc Anesth* 2003; 17: 22–28.
53. Lahoorpour F, Delpisheh A, Afkhamzadeh A. Risk factors for acquisition of ventilator-associated pneumonia in adult intensive care units. *Pakistan J Med Sci* 2013; 29: 1105–1107.
54. Bassi GL, Ferrer M, Marti JD, et al. Ventilator-associated pneumonia. In: *Seminars in respiratory and Critical care medicine*. Thieme Medical Publishers, 2014, pp. 469–481.
55. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis* 2004; 39: 206–217.
56. Sotillo-Díaz JC, Bermejo-López E, García-Olivares P, et al. Role of plasma procalcitonin in the diagnosis of ventilator-associated pneumonia: Systematic review and metaanalysis. *Med Intensiva (English Ed)* 2014; 38: 337–346.
57. Wang J, Gao Y, Zhu J, et al. Serum procalcitonin levels in predicting the prognosis of severe pneumonia patients and its correlation with white blood cell count and C-reactive protein levels. *Int J Clin Exp Med* 2020; 13: 809–815.